Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HAO2 | Q9NYQ3 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | RPA1 | P27694 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894800 | 0.77 | MAP3K14 (0.41) | MAPTKMT2AHCAR2HTT | |
| SCHEMBL11938648 | 0.76 | CCNA2 (0.57) | MAPKAPK2CYP1A2MEN1LMNAMAPT | |
| SCHEMBL12499727 | 0.72 | MEN1 (0.49) | MAPKAPK2CYP1A2MEN1LMNAMAPT | |
| SCHEMBL9941063 | 0.72 | CDK2 (0.46) | CYP1A2MEN1LMNAMAPTCYP2C9 | |
| SCHEMBL11024059 | 0.70 | MAPKAPK2 (0.47) | MAPKAPK2MEN1MAPTKMT2A | |
| Trifluoroacetic Acid SCHEMBL9940945 | 0.69 | CDK2 (0.53) | — | |
| SCHEMBL3515853 | 0.67 | HAO2 (0.42) | KMT2AHCAR2HAO2CA12ALPL | |
| SCHEMBL3503647 | 0.67 | CCNA2 (0.39) | — | |
| SCHEMBL28206510 | 0.66 | MEN1 (0.46) | CYP1A2MEN1LMNAMAPTCYP2C9 | |
| SCHEMBL9940817 | 0.66 | CDK2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614065-B1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-04-19 | — | — | EP | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541576-B2 | Substituted pyrazolo-quinazoline derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-07-26 | — | — | US | disclosed |
| WO-2012080990-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190678-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | MAPKAPK2 30/4885CYP1A2 3444/4885MEN1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.